Study guide
19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
Key Takeaways Explain This Topic AI
The biopsychosocial model explains chronic pain as an interaction of tissue factors, thoughts, emotions and social context; catastrophising and fear-avoidance beliefs predict disability more strongly than imaging findings.
Multidisciplinary pain management programmes combine cognitive behavioural or acceptance-based therapy, graded activity and pacing, education and medication review, and aim to improve function rather than eliminate pain.
Long-term opioids give little benefit in chronic non-cancer pain, and the risk of harm rises substantially above about 120 mg oral morphine equivalent per day without additional benefit (Faculty of Pain Medicine guidance).
For conversion in palliative care, oral morphine is roughly twice as potent by the subcutaneous route (divide the oral dose by about 2), and oral oxycodone is about 1.5-2 times as potent as oral morphine.
Noisy respiratory secretions at the end of life can be reduced with antimuscarinics such as glycopyrronium or hyoscine butylbromide, and terminal agitation is commonly treated with subcutaneous midazolam after reversible causes are considered.
Last updated: October 2026
- 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
- The Biopsychosocial Model of Pain
Pain is defined by the International Association for the Study of Pain as "an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage" (2020 revision). Chronic pain (lasting more than 3 months) is best understood through the biopsychosocial model :
- Domain Examples
- Biological Tissue injury, nerve damage, central sensitisation, sleep disturbance
- Psychological Catastrophising, fear-avoidance, low mood, anxiety, low self-efficacy, past trauma
- Social Work and financial stress, family responses, litigation, cultural beliefs
Central sensitisation and changes in descending modulation mean that pain can persist after tissue healing. The degree of tissue damage often correlates poorly with pain and disability.
Psychological Factors
Catastrophising: exaggerated negative thinking about pain (rumination, magnification, helplessness) predicts higher pain, more opioid use and worse outcomes, including after surgery.
Fear-avoidance: fear of pain or reinjury leads to avoidance of activity, deconditioning and disability, which reinforce pain.
Depression and anxiety are common and bidirectionally linked with chronic pain.
"Yellow flags" in back pain are psychosocial factors that predict long-term disability (for example belief that pain is harmful, low mood, passive coping, social withdrawal).
Placebo and nocebo effects: expectations change pain. Negative wording ("this will hurt a lot") increases pain through nocebo mechanisms, so careful communication during procedures matters.
Chronic Postsurgical Pain
About 10% of patients develop persistent pain after surgery, with higher rates after amputation, thoracotomy, mastectomy and hernia repair. Risk factors include severe acute postoperative pain, preoperative pain, psychological vulnerability (anxiety, catastrophising) and nerve injury. Good acute pain control and nerve-sparing surgical techniques may reduce the risk.
Multidisciplinary Pain Management
Pain management programmes (PMPs) involve psychologists, physiotherapists, nurses, occupational therapists and physicians. Components include:
Cognitive behavioural therapy (CBT): identifying and changing unhelpful thoughts and behaviours.
Acceptance and commitment therapy (ACT): accepting pain while pursuing valued activities.
Graded activity and pacing: gradual increases in activity rather than cycles of overactivity and rest.
Education: explaining pain neuroscience, reducing fear.
Medication review: rationalising and often reducing opioids and other drugs.
Return to work and social goals.
The aim is better function and quality of life , not necessarily lower pain scores. Interventional procedures (radiofrequency denervation, spinal cord stimulation) are most effective when combined with rehabilitation in selected patients.
Long-Term Opioid Therapy in Non-Cancer Pain
Evidence for long-term benefit is weak; tolerance, hyperalgesia, endocrine suppression (hypogonadism), immunosuppression, falls, dependence and overdose are significant harms.
UK Faculty of Pain Medicine guidance (Opioids Aware) states that the risk of harm increases substantially above about 120 mg oral morphine equivalent per day with no increase in benefit.
Agree goals and a trial period, review regularly, and taper opioids that do not deliver meaningful functional benefit.
Opioid-induced hyperalgesia (increasing pain with increasing doses) may improve with dose reduction.
For surgery in opioid-tolerant patients: continue the baseline opioid, use multimodal analgesia (ketamine, regional techniques), expect higher requirements, and plan the postoperative taper.
Buprenorphine patients can usually continue their usual dose perioperatively, with additional full agonists as needed.
- Palliative and End-of-Life Symptom Control
- Pain
Cancer pain follows the WHO analgesic ladder principles: by the mouth, by the clock, by the ladder, and for the individual, with adjuvants (corticosteroids for liver capsule or nerve compression pain, gabapentinoids for neuropathic pain, bisphosphonates and radiotherapy for bone pain).
- Conversion (approximate) Ratio
- Oral morphine to subcutaneous morphine Divide by about 2
- Oral morphine to oral oxycodone Divide by about 1.5-2
- Oral oxycodone to subcutaneous oxycodone Divide by about 1.5-2
Oral morphine 24-hour dose to transdermal fentanyl About 60-90 mg/day oral morphine corresponds to fentanyl 25 μ g/h \mu\text{g/h} μ g/h (product tables vary)
Breakthrough doses are usually about one-sixth of the 24-hour regular dose.
When switching between opioids, reduce the calculated dose by about 25-50% because of incomplete cross-tolerance.
In renal impairment , avoid accumulation of morphine metabolites; oxycodone in reduced doses, fentanyl or alfentanil are alternatives.
Methadone conversion is non-linear and should be specialist-led.
Subcutaneous Infusions (Syringe Drivers)
Continuous subcutaneous infusions over 24 hours are used when oral intake is not possible. Common drugs include opioids, midazolam, levomepromazine, haloperidol, glycopyrronium and hyoscine butylbromide; compatibility of mixtures must be checked.
Other Symptoms
Symptom Common management
Breathlessness Treat reversible causes; fan and positioning; low-dose opioids reduce the sensation of breathlessness; benzodiazepines for associated anxiety
Nausea and vomiting Choose by cause: haloperidol (chemical or metabolic), metoclopramide (gastric stasis, avoid in bowel obstruction with colic), cyclizine (raised intracranial pressure or vestibular), levomepromazine (broad spectrum)
Malignant bowel obstruction Hyoscine butylbromide or octreotide to reduce secretions; dexamethasone; venting gastrostomy
- Noisy respiratory secretions Repositioning; antimuscarinics (glycopyrronium, hyoscine butylbromide)
- Terminal agitation Exclude urinary retention, pain, hypoxia, drugs; midazolam; levomepromazine or haloperidol
- Ethical Principles
The doctrine of double effect : giving drugs to relieve suffering is ethical even if death may be hastened as a foreseen but unintended effect, provided the intention is symptom relief and the doses are proportionate.
Advance care planning and documented decisions about resuscitation and escalation should be discussed with patients and families.
Withdrawing life-sustaining treatment in intensive care should be accompanied by proactive symptom control.